Technology
TEAM MEMBERS
Dr. Bart Sanders
Dr. Golo von Basum
Marieke Trommelen
MEDICAL ADVISORY BOARD
prof. Serruys
Prof. van Sambeek
prof. Onuma
News
STENTiT Announces the Appointment of a Medical Advisory Board, Chaired by Prof. Patrick Serruys and Complemented by Prof. Marc van Sambeek and Prof. Yoshinobu Onuma
STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for treatment of cardiovascular diseases, today announced the appointment of its Medical Advisory Board, chaired by Prof. Patrick Serruys and complemented by Prof. Marc van Sambeek and Prof. Yoshinobu Onuma. Bart Sanders, CEO of STENTiT, said: “We are excited to receive the support of[…]
STENTiT appoints Golo von Basum as Chief Operating Officer
STENTiT, a medical device company bringing a novel class of regenerative stents for sustained endovascular repair, has appointed Dr. Golo von Basum (picture) as its Chief Operating Officer (COO). He will be responsible for the strategic implementation to scale and standardize the product development and company operations. Golo brings more than 16 years of experience in[…]
STENTiT Presenting at MedTech Strategist Virtual Innovation Summit Dublin 2021
STENTiT will present at this year’s MedTech Strategist Innovation Summit Dublin to key investors, highlighting how we address the unmet need of sustained vascular repair, with a unique concept of regenerative stents. MedTech Strategist is helping to manage the multitudes of decisions, challenges and opportunities facing the global MedTech industry. In its 8th-year, Innovation Summit[…]
IME Medical Electrospinning and STENTiT Enter Into Development Cooperation
IME Medical Electrospinning, a global leader in electrospun medical devices, today announced that it has entered into a collaboration with Dutch medical device company STENTiT, to join forces in the further development and production of regenerative endovascular support grafts. These resorbable fibrous implants hold the promise to rebuild a new blood vessel inside the existing[…]
STENTiT publishes promising results on the regenerative potential of its endovascular implants
Biodegradable implants with stenting capacity, now may regenerate vascular tissue within arteries, as shown in a proof-of-concept study conducted by STENTiT and the Eindhoven University of Technology. These implants hold the potential to restore affected arteries in a minimally invasive way, by exploiting the natural healing response of the body. The results are now published in[…]
STENTiT Meets With Foreign Ambassadors During The Dutch Design Week Economics Relations Event
On Monday October 21, the Major of Eindhoven and Chairman of the Brainport Foundation, John Jorritsma, received a group of 10 Ambassadors and Trade and Innovation Representatives from foreign embassies in The Netherlands for a Dutch Design Week Economics Relations Event. The aim of this gathering was to organize meetings and interactions with local entrepreneurs[…]
European Commission’s Seal of Excellence for STENTiT
In the highly competitive call of the Horizon 2020 SME instrument, STENTiT was awarded the European Commission’s Seal of Excellence. A recognised high-quality label for business development proposals, evaluated by an international pannel of independent experts on: 1) impact, 2) excellence, and 3) quality and efficiency of implementation. The European recognition to recommend STENTiT for[…]
STENTiT Finalist in the TCT Shark Tank Competition
On Thursday September 27th, STENTiT will participate as one of the finalists in the Shark Tank Competition during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. TCT is the annual scientific symposium organized by the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Now in its 31st[…]
Prince Constantijn and Miss Ivanka Trump award STENTiT for both Outstanding Woman Entrepreneur and GIST Health Runner-Up during the GES
During the Global Entrepreneurship Summit (GES), STENTiT proudly participated in the Global Innovation through Science & Technology (GIST) Catalyst pitch competition, organised in collaboration with the Dutch Academic Start-Up Competition. The GIST Catalyst competition began with over 4,000 applications from all over the world, which narrowed down to a list of top 30 companies giving[…]
STENTiT Selected to Pitch on Global Entrepreneurship Summit 2019
On Tuesday June 4th, STENTiT will be presenting during the Global Entrepreneurship Summit (GES) 2019 at the World Forum in The Hague. The presentation is part of the GIST Catalyst & Academic Olympics Pitch session held at 15:00 in the Europe room. The program provides Science & Technology entrepreneurs throughout the world with the opportunity[…]
STENTiT wins top ten list of most groundbreaking innovations in science
Stentit is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer. As a result of the selection, Stentit will be able to pitch at the Global Entrepreneurship Summit (GES) and will be[…]
STENTiT Nominated for the Most Pioneering Innovations in Science
STENTiT has been nominated for the Academic Startup Competition 2019. Together with 26 other nominees, STENTiT is fighting for a place in the top ten of the most pioneering innovations of science in the Netherlands. The Academic Startup Competition is an initiative of VSNU, the Dutch Academy of Technology and Innovation (AcTI) and StartupDelta. The[…]
STENTiT’s Regenerative Stent Technology at ICI 2018 in Tel Aviv
STENTiT’s promising first in-vivo data will be presented at the premier international meeting for innovation in cardiovascular systems, ICI 2018 event in Tel Aviv, Israël. Dr. Yoshinobu Onuma MD PhD, from the Erasmus Medical Center of Rotterdam, will present STENTiT’s scientific evidence and clinical applications of the regenerative stent technology in the session; “Stents –[…]
HRH Prince Constantijn highlights STENTiT among the 10 Dutch Breakthrough Technologies
This year at CES Unveiled Amsterdam, Special Envoy StartupDelta Constantijn van Oranje announced the 10 Dutch Breakthrough Technologies of 2018. Among the impressive list, STENTiT was proudly highlighted in the field of Regenerative Medicine. The list has been compiled in consultation with leading academics, investors and industry experts to showcase the next big dutch breakthrough[…]
STENTiT Receives EIT Health Funding
The health division from the European Institute of Innovation and Technology (EIT Health), provides financial support to STENTiT from the Headstart Funding Programme. The money is granted to support further product development and market validation of the regenerative stent. EIT Health provides funding for early stage companies and SMEs to develop new products and services.[…]
MIT-Zuid Subsidy for STENTiT
STENTiT obtains financial support from MKB Innovatiestimulering Topsectoren Zuid-Nederland (MIT-Zuid). This program will provide funds to conduct a technical and economic feasibility study to develop a regenerative stent for children suffering from congenital heart defects. MIT-Zuid is a program in which the 12 Dutch Provinces, the Ministry of Economic affairs and Climate, the Dutch Topsectors[…]
Gerard & Anton Award for STENTiT
During the 5th edition of the Gerard and Anton Awards, STENTiT was selected as one of the top 10 most promising start-up companies to watch 2018. With this award, the jury wants to highlight start-ups in the Brainport region that have the potential to become the next Philips. According to the jury, STENTiT is providing[…]
STENTiT’s Regenerative Stent Approach at PCR Innovators Day Paris 2018.
STENTiT will present at this year’s PCR Innovators Day Paris. In a session dedicated to stents and scaffolds, the managing directors will kick-off the programme with their presentation entitled “Stentit – Regenerative stents – Minimally invasive vascular restoration”, highlighting their innovative technological approach and promising first in-vivo data. The presentation is scheduled for 16:55 CEST[…]